Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

In summary, there is a compelling rationale for investigating venetoclax as an intervention to sensitise virus-expressing cells to apoptosis and thereby reduce the size of the latent HIV reservoir. While this concept may ultimately need to be tested in the setting of concomitant latency reversal, the investigators propose to initially establish the safety of venetoclax in PLWH on ART. The investigators will use this study to also investigate effects of venetoclax monotherapy on proapoptotic pathways, immune effector function and HIV persistence in PLWH on ART and through these studies establish the rationale for subsequent studies testing venetoclax in combination with an LRA.

NCT Number	NCT05668026
Lead Sponsor	University of Aarhus Collaborators: The Peter Doherty Institute for Infection and Immunity, Walter and Eliza Hall Institute of Medical Research, The Alfred, Aarhus University Hospital
Conditions	HIV-1-infection
Enrollment	18 participants
Start Date	2024-04-01
Primary Completion	2026-03-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-01